The Journal of Urology
Volume 183, Issue 1 , Pages 234-240, January 2010

Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder

  • Scott A. MacDiarmid

      Affiliations

    • Alliance Urology Specialists, Greensboro, North Carolina
    • Corresponding Author InformationCorrespondence: Alliance Urology Specialists, Bladder Control and Pelvic Pain Center, 509 N. Elam Ave., Second Floor, Greensboro, North Carolina 27403 (telephone: 336-274-1114; FAX: 336-232-5337)
    • Financial interest and/or other relationship with Uroplasty, Pfizer, Watson, Astellas and Allergan.
  • ,
  • Kenneth M. Peters

      Affiliations

    • William Beaumont Hospital, Royal Oak, Michigan
    • Financial interest and/or other relationship with Medtronic, Advanced Bionics, Boston Scientific, Allergan, Pfizer, Celgene and Trillium Therapeutics.
  • ,
  • S. Abbas Shobeiri

      Affiliations

    • University of Oklahoma, Oklahoma City, Oklahoma
  • ,
  • Leslie S. Wooldridge

      Affiliations

    • Mercy Health Partners, Muskegon, Michigan
    • Financial interest and/or other relationship with Uroplasty, Astellas and Watson.
  • ,
  • Eric S. Rovner

      Affiliations

    • Medical University of South Carolina, Charleston, South Carolina
    • Financial interest and/or other relationship with Uroplasty, Pfizer, Allergan, Tengion, Solace, Contura and Astellas.
  • ,
  • Fah Che Leong

      Affiliations

    • St. Louis University, St. Louis, Missouri
    • Financial interest and/or other relationship with Astellas.
  • ,
  • Steven W. Siegel

      Affiliations

    • Metro Urology, Woodbury, Minnesota
    • Financial interest and/or other relationship with AMS, Medtronic, Uromedica, Uroplasty and QiG.
  • ,
  • Susan B. Tate

      Affiliations

    • University of Louisville, Louisville, Kentucky
    • Financial interest and/or other relationship with C. R. Bard.
  • ,
  • Brian A. Feagins

      Affiliations

    • Dallas Center for Pelvic Medicine, Dallas, Texas
    • Financial interest and/or other relationship with Medtronic, AMS, Novartis, Allergan, Astellas and Boston Scientific.

Received 20 June 2009 published online 13 November 2009.

Purpose

The Overactive Bladder Innovative Therapy Trial during phase 1 was a randomized trial demonstrating comparable effectiveness of percutaneous tibial nerve stimulation and extended-release tolterodine during 12 weeks of therapy for frequency, nocturia, urgency, voided volume and urge incontinence episodes. In this second phase of the Overactive Bladder Innovative Therapy Trial we assessed the sustained therapeutic efficacy of percutaneous tibial nerve stimulation in subjects with overactive bladder during 1 year.

Materials and Methods

After 12 weeks subjects randomized to weekly percutaneous tibial nerve stimulation with Urgent® PC were offered an additional 9 months of treatment with assessments at 6 and 12 months from baseline. Outcome measures included voiding diary data, overactive bladder questionnaires, global response assessments and safety assessments.

Results

A total of 33 percutaneous tibial nerve stimulation responders continued therapy with 32 and 25 subjects completing 6 and 12 months of therapy, respectively. Subjects received a mean of 12.1 treatments during an average of 263 days, with a mean of 21 days (median 17) between treatments. Subject global response assessments showed sustained improvement from 12 weeks at 6 and 12 months, with 94% and 96% of responders, respectively. At 12 months mean improvements from baseline included a frequency of 2.8 voids daily (p <0.001), urge incontinence of 1.6 episodes daily (p <0.001), nocturia with 0.8 voids (p <0.05) and a voided volume of 39 cc (p <0.05). Overactive bladder questionnaire symptom severity was significantly improved from 12 weeks to 12 months (p <0.01) as well as from 6 to 12 months (p <0.01). No serious adverse events occurred.

Conclusions

Statistically significant overactive bladder symptom improvement achieved with 12 weekly percutaneous tibial nerve stimulation treatments demonstrates excellent durability through 12 months. The durability of response demonstrates the effectiveness of percutaneous tibial nerve stimulation as a viable, long-term therapy for overactive bladder.

Key Words: electric stimulation therapy, nocturia, tibial nerve, urinary bladder, overactive, urinary incontinence, urge

Abbreviations and Acronyms: GRA, global response assessment, OAB, overactive bladder, OAB-q, Overactive Bladder Questionnaire, OrBIT, Overactive Bladder Innovative Therapy, PTNS, percutaneous tibial nerve stimulation, SNS, sacral nerve stimulation

 

 Supported by Uroplasty, Inc.

 Study received institutional review board approval.

 See Editorial on page 17.

PII: S0022-5347(09)02381-7

doi:10.1016/j.juro.2009.08.160

Refers to article:

  • Neuromodulation—Who, What, When, Where and Why? , 13 November 2009

    Robert Mayer
    The Journal of Urology January 2010 (Vol. 183, Issue 1, Pages 17-18)

The Journal of Urology
Volume 183, Issue 1 , Pages 234-240, January 2010